JP Morgan Chase’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-15,900
Closed -$61.5K 7368
2025
Q2
$61.5K Buy
+15,900
New +$86K ﹤0.01% 5837
2024
Q2
Sell
-49,300
Closed -$502K 7319
2024
Q1
$502K Buy
+49,300
New +$501K ﹤0.01% 4795
2022
Q4
Sell
-37,200
Closed -$475K 6513
2022
Q3
$475K Buy
+37,200
New +$549K ﹤0.01% 4499

Other funds holding ALT

JP Morgan Chase's ALT Position: Q1 2026 in Review

JP Morgan Chase increased its Altimmune (ALT) stake by 22% in Q1 2026, buying an estimated $97.5K and bringing the position to 127,498 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #5192.

JP Morgan Chase first reported a position in ALT in Q4 2016 and has held it in 27 quarters since. The position peaked at $8.31M in Q3 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • JP Morgan Chase held 127,498 shares of Altimmune worth $367K as of Q1 2026.
  • JP Morgan Chase bought 22,966 Altimmune shares in Q1 2026, an estimated $97.5K.
  • Altimmune made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5192 holding.
  • JP Morgan Chase first reported a position in Altimmune in Q4 2016 and has held it in 27 quarters since.
  • JP Morgan Chase's Altimmune position peaked at $8.31M in Q3 2022.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.